Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.

Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.

Item

http://www.wikidata.org/entity/Q47276595

Q47276595

about

Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.

Item

http://www.wikidata.org/entity/Q47276595

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Reduction of methotrexate and ...... ice based on the IORRA cohort.

@en

Reduction of methotrexate and ...... ice based on the IORRA cohort.

@nl

type

Item

label

Reduction of methotrexate and ...... ice based on the IORRA cohort.

@en

Reduction of methotrexate and ...... ice based on the IORRA cohort.

@nl

prefLabel

Reduction of methotrexate and ...... ice based on the IORRA cohort.

@en

Reduction of methotrexate and ...... ice based on the IORRA cohort.

@nl

P1476

Reduction of methotrexate and ...... ice based on the IORRA cohort.

@en

P2093

Atsuo Taniguchi

http://www.w3.org/2001/XMLSchema#string

Ayako Nakajima

http://www.w3.org/2001/XMLSchema#string

Eiichi Tanaka

http://www.w3.org/2001/XMLSchema#string

Eisuke Inoue

http://www.w3.org/2001/XMLSchema#string

Hisashi Yamanaka

http://www.w3.org/2001/XMLSchema#string

Kumi Shidara

http://www.w3.org/2001/XMLSchema#string

Naoki Sugimoto

http://www.w3.org/2001/XMLSchema#string

Shigeki Momohara

http://www.w3.org/2001/XMLSchema#string

Yohei Seto

http://www.w3.org/2001/XMLSchema#string

Yoko Shimizu

http://www.w3.org/2001/XMLSchema#string

P2860

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.

Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14397595.2017.1369926

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28880684

http://www.w3.org/2001/XMLSchema#string

Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.

about

Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698